New depression pill JS1-1-01 enters key trials

NCT ID NCT07485595

Not yet recruiting Symptom relief Sponsor: Tasly Pharmaceutical Group Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tests an experimental tablet called JS1-1-01 in 180 adults with moderate to severe depression. Participants will take either a low dose, high dose, or placebo for 8 weeks. The goal is to see if the drug safely reduces depression symptoms better than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: JS1-1-01 tablet
What this could lead to: If this trial succeeds, it could point toward a new oral medication to ease symptoms of moderate to severe depression.
What could go wrong: This is an early combined phase 2/3 trial with only 180 participants. The drug may not prove more effective than placebo, and side effects are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION

Contacts and locations

Locations

Gang Wang

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.